» Authors » Irina Chafeeva

Irina Chafeeva

Explore the profile of Irina Chafeeva including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 15
Citations 90
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Ji H, Yu K, Abbina S, Xu L, Xu T, Cheng S, et al.
Nat Mater . 2024 Nov; PMID: 39533064
Antithrombotic surfaces that prevent coagulation activation without interfering with haemostasis are required for blood-contacting devices. Such materials would restrain device-induced thrombogenesis and decrease the need for anticoagulant use, thereby reducing...
2.
La C, Smith S, Vappala S, Adili R, Luke C, Abbina S, et al.
Nat Commun . 2023 Apr; 14(1):2177. PMID: 37100783
Current treatments to prevent thrombosis, namely anticoagulants and platelets antagonists, remain complicated by the persistent risk of bleeding. Improved therapeutic strategies that diminish this risk would have a huge clinical...
3.
Du C, Jayo R, Mendelson A, Chafeeva I, da Roza G, Liggins R, et al.
Perit Dial Int . 2023 Jan; 43(4):324-333. PMID: 36588412
Background: Small hyperbranched polyglycerol (HPG) has been recently of interest for peritoneal dialysis, but its pharmacokinetics is barely understood. This study investigated the absorption, distribution and excretion of 1 and...
4.
Liu B, Feng S, Dairi G, Guan Q, Chafeeva I, Wang H, et al.
BMC Nephrol . 2019 May; 20(1):181. PMID: 31113397
Background: Glucose is a primary osmotic agent in peritoneal dialysis (PD) solutions, but its long-term use causes structural alteration of the peritoneal membrane (PM). Hyperbranched polyglycerol (HPG) is a promising...
5.
Han B, Guan Q, Chafeeva I, Mendelson A, da Roza G, Liggins R, et al.
Basic Clin Pharmacol Toxicol . 2018 May; 123(4):494-503. PMID: 29753311
Metabolic syndrome (MetS) is commonly observed among peritoneal dialysis (PD) patients, and hyperbranched polyglycerol (HPG) is a promising glucose-sparing osmotic agent for PD. However, the biocompatibility of a HPG-based PD...
6.
Wong N, Shenoi R, Abbina S, Chafeeva I, Kizhakkedathu J, Khan M
Biomacromolecules . 2017 Jun; 18(8):2427-2438. PMID: 28655275
Three hyperbranched polyglycerol nanoparticle (HPG NP) variants were synthesized and fluorescently labeled for the study of their cellular interactions. The polymeric nanoparticle that contains a hydrophobic core and a hydrophilic...
7.
Li S, Liu B, Guan Q, Chafeeva I, Brooks D, Nguan C, et al.
Am J Transl Res . 2017 Mar; 9(2):429-441. PMID: 28337272
Minimizing donor organ injury during cold preservation (including cold perfusion and storage) is the first step to prevent transplant failure. We recently reported the advantages of hyperbranched polyglycerol (HPG) as...
8.
Du C, Mendelson A, Guan Q, Dairi G, Chafeeva I, da Roza G, et al.
J Transl Med . 2016 Dec; 14(1):338. PMID: 27964722
Background: Replacing glucose with a better biocompatible osmotic agent in peritoneal dialysis (PD) solutions is needed in PD clinic. We previously demonstrated the potential of hyperbranched polyglycerol (HPG) as a...
9.
Wong N, Misri R, Shenoi R, Chafeeva I, Kizhakkedathu J, Khan M
J Biomed Nanotechnol . 2016 Jun; 12(5):1089-100. PMID: 27305828
PEGylation is commonly used to increase the plasma residence time of anticancer drug nanocarriers. However, PEGylation may trigger antibody production and lead to accelerated blood clearance in subsequent administrations. Moreover,...
10.
Misri R, Wong N, Shenoi R, Lum C, Chafeeva I, Toth K, et al.
Nanomedicine . 2015 May; 11(7):1785-95. PMID: 25981338
From The Clinical Editor: The use of polyethylene glycol on nano-carriers as "stealth" to deliver intravenous drugs is well known. Here, the authors developed polymeric nanoparticle (NP) with hyperbranched polyglycerol...